[Quality of life in the treatment assessment of postmenopausal osteoporosis].
OBJECTIVE
To evaluate quality of life (QOL) in the treatment assessment of postmenopausal osteoporosis (PMOP) by comparing the QOL of three treatments: hormone replacement treatment, supplement of calcium and vitamin D and risedronate.


METHODS
All patients with postmenopausal osteoporosis (PMOP) in this clinical trial had been allocated into 4 groups: placebo therapy group, vitamin D addition calcium therapy group, hormone replacement treatment (HRT) therapy group, and risedronate therapy group. We measured the bone mineral density (BMD) and quality of life sale (QOLS) of patients in three times, before the treatment, 3 months after the treatment,and 12 months after the treatment. The differences of the QOL and BMD at the 4 groups and at different time, the linear correlation of the change of QOL and the change of BMD, were both compared after the measurement.


RESULTS
The total score of QOL and the score of disease domain and physical domain of HRT therapy group and risedronate therapy group were higher than the placebo therapy group (F = 17. 335, P <0.001), but vitamin D addition calcium therapy group was not different from that of the placebo therapy group. The score of other three domains had no statistically significant difference among the 4 groups. The score of disease domain of the patients of risedronate therapy group started to increase after 3 months of treatment, and continued to increase after 12 months of treatment. The score of disease domain of the patients of HRT therapy group started to increase only after 12 months of treatment. But the score of disease domain of the patients of vitamin D addition calcium therapy group did not increase after 12 months of treatment. The changes of the score of disease domain had the linar correlation with the changes of BMD, and the correlation coefficient was from 0.608 to 0.827.


CONCLUSIONS
QOL may become one of the indexes of medical treatment outcome assessment system for PMOP.
Hu
Yu-Feng
YF
Department of Epidemiology and Health Statistics , Public Health College, Central South University, Changsha 410078, China.
Sun
Zhen-Qiu
ZQ
D015502:Absorptiometry, Photon; D019386:Alendronate / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life; D014807:Vitamin D / Q000627:therapeutic use*
D014807:Vitamin D; D019386:Alendronate